Akeso, Inc. (AKESO) financials

HKSE · Healthcare · Biotechnology · 4,082 employees · CEO Yu Xia

Price: HK$78.90 -3.19%
Market cap: HK$72.7B
Enterprise value: CN¥57.8B
Last report: Q2 '26 filed 2026-06-30
Next report: 2027-03-31

Revenue (TTM)–– vs a year agoLast 4 quarters; bars = each quarter

Operating margin (TTM)–– vs a year agoOperating income –

Net income (TTM)–– vs a year agoAfter tax, incl. non-operating gains

Free cash flow (TTM)–– vs a year agoCapex –

Diluted EPS (TTM)–– vs a year agoSum of the last 4 quarters

Net cashCN¥4.17B+32.8% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap: HK$72.7B
Revenue: –
Revenue growth: –
Profit margin: –
P/E: -64.2×
P/S: 18.1×
EV / EBITDA: -74.2×
Free cash flow: –
Net income: –
Revenue estimate: –
Earnings: 2027-03-31
Dividend: –

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

Revenue growth accelerating: 26.2% year on yearQ2 '26 revenue CN¥1.78B, against an average of 10.5% over the four quarters before.
Diluted share count up 2.6% in a year919M diluted shares in Q2 '26, 895M a year earlier.
Net cash CN¥4.17BCash + short-term investments CN¥9.16B, debt incl. leases CN¥4.98B; a year ago net cash CN¥3.14B.

Last quarter: Q2 '26

Quarter ended 2026-06-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

	Q2 '26	Year ago	Change
Revenue	CN¥1.78B	CN¥1.41B	+26.2%
Gross margin	74.2%	79.4%	-5.2 pp
Operating income	-CN¥279M	-CN¥414M	+32.8%
Operating margin	-15.6%	-29.4%	+13.7 pp
Net income	-CN¥418M	-CN¥570M	+26.6%
Diluted EPS	-CN¥0.46	-CN¥0.64	+28.1%
Operating cash flow	CN¥222M	-CN¥228M	+197.5%
Capex	CN¥326M	CN¥480M	-32.1%
Free cash flow	-CN¥104M	-CN¥228M	+54.2%
R&D	CN¥773M	CN¥731M	+5.6%
Stock-based compensation	CN¥0	CN¥27.2M	-100.0%

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 4 quarters

cash flow statement

Free cash flow: –
Returned to shareholders / FCF: –

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years

	Now	5y average	Where today sits in the 5-year range
P/E (TTM)	-64.2×	17.4× 1 of 5 years	17.4× – 17.4×
EV / EBITDA	-74.2×	15.7× 1 of 5 years	15.7× – 15.7×
EV / Sales	17.0×	37.5×	7.6× – 92.2×
Price / FCF	-49.5×	22.2× 1 of 5 years	22.2× – 22.2×
Price / Book	7.2×	8.8×	7.1× – 11.9×
FCF yield	-2.0%	-2.8%	-7.6% – 4.5%
Return on invested capital	-5.3%	-9.6%	-32.1% – 24.4%
Return on equity	-10.9%	-10.9%	-44.3% – 43.2%

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Income statementRevenue, costs, operating income, net income and EPSOpen Balance sheetCash, investments, assets, debt, liabilities and equityOpen Cash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-02 · Amounts in CNY as reported; price and market cap in HKD.